Clinical utility of the C‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab

BACKGROUND: Nivolumab is a second‐line chemotherapy for non‐small cell lung cancer (NSCLC). This study explored the impact of clinical biomarkers such as neutrophil:lymphocyte ratio (NLR), C‐reactive protein:albumin ratio (CAR), and modified Glasgow prognostic score on the efficacy and outcome of ni...

Descripción completa

Detalles Bibliográficos
Autores principales: Araki, Taisuke, Tateishi, Kazunari, Sonehara, Kei, Hirota, Shuko, Komatsu, Masamichi, Yamamoto, Manabu, Kanda, Shintaro, Kuraishi, Hiroshi, Hanaoka, Masayuki, Koizumi, Tomonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919135/
https://www.ncbi.nlm.nih.gov/pubmed/33434414
http://dx.doi.org/10.1111/1759-7714.13788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919135/
https://www.ncbi.nlm.nih.gov/pubmed/33434414
http://dx.doi.org/10.1111/1759-7714.13788

Ejemplares similares